SUTRO BIOPHARMA, INC. cotiza a 13.28 USD y tiene una capitalización bursátil de $220M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Sutro Biopharma, Inc. operates as an oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+. Its lead product candidate includes STRO-0…
| Periodo | 2026-08 | 2026-05 | 2026-03 | 2025-11 |
|---|---|---|---|---|
| Real | $-2.31 | $-2.94 | $-4.88 | $-5.57 |
| Estimado | $-2.29 | $-3.21 | $-4.43 | $-3.55 |
| Sorpresa | -0.9% | +8.4% | -10.2% | -56.9% |
| Métrica | STRO | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -154.5% | -38.6% | -115.9% |
| Net Margin | -186.4% | -33.6% | -152.9% |
| FCF Margin | — | -13.9% | — |
| ROE | — | -40.4% | — |
| ROA | -109.9% | -32.0% | -77.9% |
| Current Ratio | 2.01 | 2.84 | -0.83 |
| Debt / Equity | — | 0.28 | — |